Danaher Co. (NYSE:DHR) Shares Sold by WealthPLAN Partners LLC

WealthPLAN Partners LLC lessened its position in shares of Danaher Co. (NYSE:DHR - Free Report) by 28.7% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 11,159 shares of the conglomerate's stock after selling 4,484 shares during the quarter. WealthPLAN Partners LLC's holdings in Danaher were worth $3,103,000 as of its most recent SEC filing.

A number of other large investors have also added to or reduced their stakes in DHR. Vanguard Group Inc. lifted its position in Danaher by 7.4% during the first quarter. Vanguard Group Inc. now owns 60,107,030 shares of the conglomerate's stock valued at $15,009,928,000 after purchasing an additional 4,163,657 shares during the last quarter. Legal & General Group Plc increased its position in shares of Danaher by 2.4% during the 2nd quarter. Legal & General Group Plc now owns 5,964,031 shares of the conglomerate's stock valued at $1,490,112,000 after purchasing an additional 139,989 shares during the last quarter. Capital Research Global Investors raised its holdings in Danaher by 1.0% during the 1st quarter. Capital Research Global Investors now owns 5,125,470 shares of the conglomerate's stock valued at $1,279,932,000 after buying an additional 52,679 shares during the period. Dimensional Fund Advisors LP lifted its position in Danaher by 2.6% in the second quarter. Dimensional Fund Advisors LP now owns 3,398,649 shares of the conglomerate's stock worth $849,195,000 after buying an additional 85,081 shares during the last quarter. Finally, Massachusetts Financial Services Co. MA boosted its stake in Danaher by 22.7% during the second quarter. Massachusetts Financial Services Co. MA now owns 3,047,728 shares of the conglomerate's stock worth $761,475,000 after buying an additional 563,546 shares during the period. Institutional investors own 79.05% of the company's stock.

Analyst Upgrades and Downgrades

Several analysts have recently weighed in on the company. UBS Group decreased their target price on Danaher from $309.00 to $305.00 and set a "buy" rating for the company in a research report on Wednesday, October 23rd. Bank of America boosted their price target on Danaher from $270.00 to $275.00 and gave the stock a "neutral" rating in a research report on Wednesday, July 24th. Evercore ISI increased their target price on shares of Danaher from $275.00 to $278.00 and gave the company an "outperform" rating in a research report on Tuesday, October 1st. Wolfe Research raised Danaher from a "peer perform" rating to an "outperform" rating and set a $285.00 target price on the stock in a research report on Thursday, October 31st. Finally, The Goldman Sachs Group boosted their price target on Danaher from $225.00 to $250.00 and gave the stock a "neutral" rating in a research note on Wednesday, July 24th. Five research analysts have rated the stock with a hold rating and fifteen have assigned a buy rating to the company's stock. According to data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and a consensus target price of $287.16.

Insider Buying and Selling at Danaher

In other news, SVP Georgeann Couchara sold 952 shares of the company's stock in a transaction that occurred on Monday, August 26th. The stock was sold at an average price of $268.37, for a total transaction of $255,488.24. Following the completion of the transaction, the senior vice president now directly owns 4,212 shares of the company's stock, valued at $1,130,374.44. This represents a 0.00 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available through this link. 11.10% of the stock is owned by corporate insiders.

Danaher Stock Performance

DHR stock traded down $1.67 during trading on Tuesday, hitting $241.58. 684,094 shares of the company traded hands, compared to its average volume of 2,738,021. The company has a debt-to-equity ratio of 0.32, a current ratio of 1.37 and a quick ratio of 1.01. Danaher Co. has a 1 year low of $193.75 and a 1 year high of $281.70. The stock's 50-day simple moving average is $264.37 and its 200 day simple moving average is $260.82. The company has a market cap of $174.49 billion, a PE ratio of 46.42, a P/E/G ratio of 4.51 and a beta of 0.85.

Danaher (NYSE:DHR - Get Free Report) last announced its quarterly earnings results on Tuesday, October 22nd. The conglomerate reported $1.71 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.57 by $0.14. Danaher had a net margin of 16.39% and a return on equity of 10.62%. The firm had revenue of $5.80 billion for the quarter, compared to the consensus estimate of $5.59 billion. During the same period in the prior year, the firm posted $2.02 earnings per share. The firm's quarterly revenue was up 3.1% compared to the same quarter last year. On average, equities analysts expect that Danaher Co. will post 7.51 earnings per share for the current fiscal year.

Danaher Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Friday, October 25th. Shareholders of record on Friday, September 27th were given a dividend of $0.27 per share. The ex-dividend date was Friday, September 27th. This represents a $1.08 dividend on an annualized basis and a yield of 0.45%. Danaher's dividend payout ratio is currently 20.61%.

Danaher Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.